Collaboration aims to improve access to new blood cancer treatments through clinical trials
NEW YORK, May 10, 2022 /PRNewswire/ — The MPN Research Foundation (MPNRF)a global organization conducting research to find new and better treatments for myeloproliferative neoplasms (MPNs), a group of rare blood cancers, and Court casethe AI-powered decision support platform for patients, healthcare providers and pharmaceutical companies, today announced a joint collaboration to bring Trialjectory AI-powered free clinical trial search tool to the MPNRF patient community. The Clinical Trials Finder tool helps match patients to the right trials for their exact diagnosis and thus increases their access to potentially life-saving new advanced treatment options.
Trialjectory’s clinical trials search tool uses the results of self-reported, user-friendly questionnaires to provide NMP patients with a curated list of matching and relevant trials. Serving as a resource for patients and a support system throughout the treatment journey, Trialjectory also provides patients with access to clinical trial specialists who meet their needs during the application and enrollment process, as well as the participation in the actual trial.
“Efficient matching of clinical trials is particularly important for patients with NMP, as diseases often include a wide range of profiles at different stages for patients,” said Kapila Viges, CEO of the MPN Research Foundation. “With Trialjectory’s sophisticated clinical trial search tool, patients have a simple, easy-to-use tool that allows them to identify the best options for their unique situation. Through this collaboration, we hope to enable patients to not only act on their own behalf, but also to contribute to better outcomes for all patients with NPM by helping to advance MPN research as a whole.”
Whether patients are searching for clinical trials when first diagnosed or when a current treatment is not working/has stopped working, Trialjectory’s clinical trials search engine also allows patients to:
Interact with a live concierge service to answer any questions they may have along the way (available in English, Spanish and French) to adequately support and encourage trial participation among patients from diverse backgrounds
Print or email essays they find interesting so they can easily share them with their oncologist to spark discussion
Receive updates when new essays match their profile, if desired
“With very few treatments currently approved for NMP, it is critical that these patients know and understand all of their available options specific to their diagnosis, symptoms and treatment history,” added Tzvia Bader, Co-founder and CEO of Trialjectory. “Clinical trials are known to often provide better outcomes for patients compared to standard treatments, and technologies such as AI can help them find and learn about trials in a way that is understandable and comprehensible. truly democratizes advanced treatment options for patients around the world facing a diagnosis of NMP. Trialjectory and the MPNRF are committed to helping these people every step of the way to ensure they have the tools they need to defeat the disease.
Trialjectory is an AI-powered decision support platform that democratizes access to advanced cancer treatments and addresses the multiple challenges facing the oncology drug development ecosystem. Its unique model informs and empowers cancer patients to take ownership of their treatment journey, supports a more personalized approach to patient care, and helps pharmaceutical companies achieve patient-centric drug development. Trialjectory has been recognized by WEATHER as one of “The 100 best inventions of 2020and named winner in the AI and Data category for fast business‘s”2021 Ideas That Change the World Award.”
For more information, please visit www.trialjectory.comand follow the Company on Facebook and LinkedIn.
About the MPN Research Foundation
The MPN Research Foundation is a world leader in conducting innovative research into myeloproliferative neoplasms, a group of rare blood cancers that includes essential thrombocythemia, polycythemia vera, and myelofibrosis. Since 2001, the non-profit association (501c3) has invested more than $16 million in research towards new treatments and improved quality of life for patients with NMP.
For more information, please visit www.mpnresearchfoundation.organd follow the Company on Facebook, Twitterand LinkedIn.
View original content: https://www.prnewswire.com/news-releases/mpn-research-foundation-and-trialjectory-partner-to-provide-advanced-clinical-trial-matching-services-for-patients-in – need-301543692.html